Cushing's SyndromeNCT00682084
Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome
An observational study of Cushing's Syndrome and Insulin Resistance, run by University of Aarhus at 1 site in Denmark.
Trial summary
The purpose of this study is to investigate the effect og chronic elevated levels of cortisol on metabolism and insulin sensitivity. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Cushing's Syndrome, Insulin Resistance
- What is being tested?
- Surgery
- Type of treatment
- Surgery or procedure
- How many people
- 1 participants
- Where
- 1 siteDenmark
- Study dates
- Apr 2008to Nov 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients recently diagnosed with Cushing's syndrome, recruited from the clinic.
Who may be able to join
- Written consent
- Age between 18 and 70
- Diagnosed with Cushing's syndrome
Who cannot join
- Suspected malignancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome Before and After Surgical Treatment
The purpose of this study is to investigate the effect og chronic elevated levels of cortisol on metabolism and insulin sensitivity.
- Conditions
- Cushing's Syndrome, Insulin Resistance
- Being tested
- Surgery
- Keywords
- Cushing's syndrome, Glucose tolerance, Insulin sensitivity, Substrate metabolism, Body composition
- Medical subject headings
- Cushing Syndrome, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurgeryProcedure or surgery
Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
| Study group | Role | What they receive |
|---|---|---|
| 1 | Patients recently diagnosed with Cushing's syndrome Receives: Procedure: Surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Insulin sensitivity
Measured: Before and after treatment
Secondary outcomes (1)
Glucose tolerance, QoL, body composition, intrahepatic and intramyocellular fat, substrate metabolism.
Measured: Before and after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2008 (estimated)
- Study startApr 2008
- Primary completionNov 2016
- Study completionNov 2016
Why it stopped: Recruitment problems
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cushing's SyndromeStudies of the same condition, open and under way.
- More trials run by University of AarhusThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Collaborators
- Aarhus University Hospital
- Responsible party
- Sponsor
- Investigators
- Jens Otto L. Jørgensen, Professor MD, Principal investigator, Aarhus University Hospital, Department of Endocrinology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00682084
- Sponsor's protocol ID
- MM-ISC-20070131
- Status last verified
- Dec 2014
- First submitted
- 20 May 2008
- Last updated
- 22 Dec 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome Before and After Surgical Treatment
- ClinicalTrials.gov ID
- NCT00682084
- Acronym / sponsor ID
- MM-ISC-20070131
- Conditions
- Cushing's Syndrome, Insulin Resistance
- Keywords
- Cushing's syndrome, Glucose tolerance, Insulin sensitivity, Substrate metabolism, Body composition
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Recruitment problems
- Enrolment
- 1 participants (actual)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Collaborators
- Aarhus University Hospital
- Study start
- Apr 2008
- Primary completion
- Nov 2016 (actual)
- Study completion
- Nov 2016 (actual)
- First posted
- 22 May 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the effect og chronic elevated levels of cortisol on metabolism and insulin sensitivity.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | Procedure: SurgeryPatients recently diagnosed with Cushing's syndrome |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients recently diagnosed with Cushing's syndrome, recruited from the clinic.
Key inclusion criteria (3 listed)
- Written consent
- Age between 18 and 70
- Diagnosed with Cushing's syndrome
Key exclusion criteria (1 listed)
- Suspected malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurgerySurgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor | Procedure or surgery | 1 |
Primary outcome
Insulin sensitivity
Time frame: Before and after treatment
1 secondary outcome
Glucose tolerance, QoL, body composition, intrahepatic and intramyocellular fat, substrate metabolism.
Time frame: Before and after treatment
Results and safety
The study was stopped early (reason given: Recruitment problems). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2017.
Related trials for Cushing's Syndrome
Not yet recruitingPhase 2
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Active, not recruitingPhase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Cushing Syndrome
RecruitingPhase 1/2
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
Cushing s Syndrome
RecruitingPhase 4
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Hypertension, Hypercortisolemia
RecruitingObservational study
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Cushing's Disease, Cushing Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jens Otto L. Jørgensen, Professor MD principal investigator
Aarhus University Hospital, Department of Endocrinology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cushing's Syndrome and Insulin Resistance, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Recruitment problems). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Insulin sensitivity (time frame: Before and after treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2017.